PharmaBoardroom

JP Morgan 2021 Virtual Healthcare Conference: A Course Correction…

David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual format, noting potential changes in…

What to Expect if Janet Woodcock Becomes Permanent FDA Head

Hours after President Biden was inaugurated on Tuesday 19th January 2021, Dr Janet Woodcock was named as acting commissioner for the Food and Drugs…

Photocure: Swimming in the “Blue Ocean” of Oncology…

Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare success story. CEO Dan Schneider…

The Long Read: Innovation, Access & Affordability in the USA

A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…

US Pharma Innovation Factsheet 2020

In a recent article for PharmaBoardroom, Objective Capital's David Crean took a look at the state of US innovation today and its long term…

The Value Proposition of Generics & Biosimilars in the USA

AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…

Rare Disease Strategies in the Booming US Market

Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…

Novartis Oncology US: Leaning into Change

With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business…